LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

10X Genomics Inc (Class A)

Geschlossen

BrancheGesundheitswesen

9.65 1.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.44

Max

9.78

Schlüsselkennzahlen

By Trading Economics

Einkommen

15M

-34M

Verkäufe

-10M

155M

EPS

-0.102

Gewinnspanne

-22.183

Angestellte

1,306

EBITDA

-1.5M

-39M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+46.47% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

108M

1.2B

Vorheriger Eröffnungskurs

7.86

Vorheriger Schlusskurs

9.65

Nachrichtenstimmung

By Acuity

50%

50%

209 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

10X Genomics Inc (Class A) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2025, 23:20 UTC

Ergebnisse

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. Mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. Mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. Mai 2025, 23:24 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

13. Mai 2025, 23:24 UTC

Market Talk
Ergebnisse

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. Mai 2025, 22:58 UTC

Ergebnisse

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. Mai 2025, 22:38 UTC

Ergebnisse

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. Mai 2025, 22:38 UTC

Ergebnisse

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. Mai 2025, 22:37 UTC

Ergebnisse

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. Mai 2025, 22:36 UTC

Ergebnisse

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. Mai 2025, 22:35 UTC

Ergebnisse

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. Mai 2025, 22:34 UTC

Ergebnisse

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. Mai 2025, 22:30 UTC

Ergebnisse

Aristocrat Interim Dividend 44 Australian Cents/Share

13. Mai 2025, 22:30 UTC

Ergebnisse

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. Mai 2025, 22:29 UTC

Ergebnisse

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. Mai 2025, 22:28 UTC

Ergebnisse

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. Mai 2025, 21:15 UTC

Ergebnisse

Nu Holdings 1Q Rev $3.2B >NU

13. Mai 2025, 21:03 UTC

Top News

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Mai 2025, 20:32 UTC

Ergebnisse

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. Mai 2025, 20:31 UTC

Ergebnisse

Alcon 1Q Sales $2.45B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q Rev $2.47B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q EPS 70c >ALC.EB

Peer-Vergleich

Kursveränderung

10X Genomics Inc (Class A) Prognose

Kursziel

By TipRanks

46.47% Vorteil

12-Monats-Prognose

Durchschnitt 13.9 USD  46.47%

Hoch 26 USD

Tief 9 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für 10X Genomics Inc (Class A) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

5

Buy

7

Halten

0

Sell

Technischer Score

By Trading Central

8.32 / 8.63Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

No Evidence

Stimmung

By Acuity

209 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.